Wilms Tumor Protein (WT33 or WT1) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Wilms Tumor Protein (WT33 or WT1) – Pipeline Review, H1 2017’, provides in depth analysis on Wilms Tumor Protein (WT33 or WT1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Wilms Tumor Protein (WT33 or WT1)Additionally, the report provides an overview of key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Wilms Tumor Protein (WT33 or WT1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)

The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects

The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Wilms Tumor Protein (WT33 or WT1) - Overview

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Wilms Tumor Protein (WT33 or WT1) - Drug Profiles

DSP-7888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galinpepimut-S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2130579A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCV-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXM-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-2725 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-4869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wilms Tumor Protein (WT33 or WT1) - Dormant Products

Wilms Tumor Protein (WT33 or WT1) - Discontinued Products

Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones

Featured News & Press Releases

May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017

Mar 30, 2017: VAXIMM to present preclinical data on VXM06m at AACR Annual Meeting 2017

Mar 01, 2017: SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Feb 27, 2017: Inovio’s SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy

Dec 06, 2016: Boston Biomedical Announces First Clinical Data for Investigational WT1 Cancer Peptide Vaccine, DSP-7888, at ASH Annual Meeting & Exposition

Dec 01, 2016: VAXIMM Presents Preclinical Data on VXM-06 at EORTC-NCI-AACR Symposium

Nov 04, 2016: Sumitomo Dainippon Pharma Announces the Data of an Investigational WT1 Cancer Peptide Vaccine, DSP-7888 will be Presented at the ASH 2016

Oct 19, 2016: SELLAS Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy OfficeR

Oct 13, 2016: SELLAS Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Oct 03, 2016: SELLAS Life Sciences Appoints Industry Experts to Support Advancement of Cancer Therapeutics Pipeline

Sep 19, 2016: SELLAS Life Sciences Receives FDA Fast Track Designation of Galinpepimut-S for the Treatment of Malignant Pleural Mesothelioma

Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting

May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting

May 04, 2016: SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig)

Apr 29, 2016: SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by GlaxoSmithKline Plc, H1 2017

Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Pipeline by Otsuka Holdings Co Ltd, H1 2017

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Pipeline by Vaximm AG, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports